Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
GI (functional) | = 100 % | Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 epimastigotes assessed as growth inhibition at 25 uM after 5 days relative to control | ChEMBL. | 21506600 |
GI50 (functional) | = 0.35 uM | Anticancer activity against nonsmall lung cancer cells | ChEMBL. | 17910426 |
GI50 (functional) | = 0.4 uM | Anticancer activity against prostate cancer cells | ChEMBL. | 17910426 |
GI50 (functional) | = 0.48 uM | Anticancer activity against renal cancer cells | ChEMBL. | 17910426 |
GI50 (functional) | = 0.75 uM | Anticancer activity against ovarian cancer cells | ChEMBL. | 17910426 |
GI50 (functional) | = 0.83 uM | Anticancer activity against colon cancer cells | ChEMBL. | 17910426 |
GI50 (functional) | = 0.85 uM | Anticancer activity against breast cancer cells | ChEMBL. | 17910426 |
GI50 (functional) | = 0.98 uM | Anticancer activity against human NCI60 cells | ChEMBL. | 17910426 |
GI50 (functional) | = 1.39 uM | Anticancer activity against melanoma cells | ChEMBL. | 17910426 |
GI50 (functional) | = 1.45 uM | Anticancer activity against CNS cancer cells | ChEMBL. | 17910426 |
GI50 (functional) | = 13.93 uM | Anticancer activity against leukemia cells | ChEMBL. | 17910426 |
ID50 (ADMET) | = 4690 nM | Cytotoxicity against mouse J774 cells | ChEMBL. | 21506600 |
ID50 (functional) | = 1100 uM | Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 epimastigotes assessed as growth inhibition after 5 days | ChEMBL. | 21506600 |
LC50 (functional) | = 11.22 uM | Anticancer activity against human NCI60 cells | ChEMBL. | 17910426 |
TGI (functional) | = 3.89 uM | Anticancer activity against human NCI60 cells | ChEMBL. | 17910426 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.